Annual EBITDA
-$269.98 M
-$61.90 M-29.75%
March 31, 2024
Summary
- As of February 12, 2025, IMVT annual EBITDA is -$269.98 million, with the most recent change of -$61.90 million (-29.75%) on March 31, 2024.
- During the last 3 years, IMVT annual EBITDA has fallen by -$161.93 million (-149.86%).
- IMVT annual EBITDA is now -311.27% below its all-time high of -$65.64 million, reached on March 31, 2020.
Performance
IMVT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$114.20 M
+$1.45 M+1.25%
December 31, 2024
Summary
- As of February 12, 2025, IMVT quarterly EBITDA is -$114.20 million, with the most recent change of +$1.45 million (+1.25%) on December 31, 2024.
- Over the past year, IMVT quarterly EBITDA has dropped by -$52.71 million (-85.71%).
- IMVT quarterly EBITDA is now -28550650.00% below its all-time high of -$400.00, reached on March 31, 2019.
Performance
IMVT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$404.87 M
-$52.71 M-14.97%
December 31, 2024
Summary
- As of February 12, 2025, IMVT TTM EBITDA is -$404.87 million, with the most recent change of -$52.71 million (-14.97%) on December 31, 2024.
- Over the past year, IMVT TTM EBITDA has dropped by -$151.50 million (-59.80%).
- IMVT TTM EBITDA is now -101218150.00% below its all-time high of -$400.00, reached on March 31, 2019.
Performance
IMVT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
IMVT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -29.8% | -85.7% | -59.8% |
| 3 y3 years | -149.9% | -176.9% | -194.2% |
| 5 y5 years | -311.3% | -955.5% | -3472.7% |
IMVT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -149.9% | at low | -183.2% | +1.3% | -194.2% | at low |
| 5 y | 5-year | -311.3% | at low | -955.5% | +1.3% | -3472.7% | at low |
| alltime | all time | -311.3% | at low | <-9999.0% | +1.3% | <-9999.0% | at low |
Immunovant EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$114.20 M(-1.3%) | -$404.87 M(+15.0%) |
| Sep 2024 | - | -$115.65 M(+22.8%) | -$352.17 M(+18.1%) |
| Jun 2024 | - | -$94.20 M(+16.6%) | -$298.25 M(+10.5%) |
| Mar 2024 | -$269.98 M(+29.7%) | -$80.81 M(+31.4%) | -$269.98 M(+6.6%) |
| Dec 2023 | - | -$61.49 M(-0.4%) | -$253.37 M(+3.1%) |
| Sep 2023 | - | -$61.74 M(-6.3%) | -$245.85 M(+5.2%) |
| Jun 2023 | - | -$65.92 M(+2.7%) | -$233.68 M(+12.3%) |
| Mar 2023 | -$208.08 M(+33.5%) | -$64.20 M(+18.9%) | -$208.08 M(+8.9%) |
| Dec 2022 | - | -$53.98 M(+8.9%) | -$191.06 M(+7.1%) |
| Sep 2022 | - | -$49.57 M(+22.9%) | -$178.32 M(+7.2%) |
| Jun 2022 | - | -$40.33 M(-14.5%) | -$166.38 M(+6.7%) |
| Mar 2022 | -$155.91 M | -$47.19 M(+14.4%) | -$155.91 M(+13.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | - | -$41.24 M(+9.6%) | -$137.62 M(+7.5%) |
| Sep 2021 | - | -$37.62 M(+26.0%) | -$128.00 M(+15.0%) |
| Jun 2021 | - | -$29.86 M(+3.3%) | -$111.34 M(+3.0%) |
| Mar 2021 | -$108.05 M(+64.6%) | -$28.89 M(-8.6%) | -$108.05 M(+8.3%) |
| Dec 2020 | - | -$31.62 M(+50.9%) | -$99.76 M(+26.3%) |
| Sep 2020 | - | -$20.96 M(-21.1%) | -$78.96 M(+35.2%) |
| Jun 2020 | - | -$26.58 M(+29.0%) | -$58.42 M(+82.9%) |
| Mar 2020 | -$65.64 M | -$20.60 M(+90.4%) | -$31.94 M(+181.8%) |
| Dec 2019 | - | -$10.82 M(+2477.4%) | -$11.33 M(+2111.2%) |
| Sep 2019 | - | -$419.80 K(+354.8%) | -$512.50 K(+452.9%) |
| Jun 2019 | - | -$92.30 K(>+9900.0%) | -$92.70 K(>+9900.0%) |
| Mar 2019 | - | -$400.00 | -$400.00 |
FAQ
- What is Immunovant annual EBITDA?
- What is the all time high annual EBITDA for Immunovant?
- What is Immunovant annual EBITDA year-on-year change?
- What is Immunovant quarterly EBITDA?
- What is the all time high quarterly EBITDA for Immunovant?
- What is Immunovant quarterly EBITDA year-on-year change?
- What is Immunovant TTM EBITDA?
- What is the all time high TTM EBITDA for Immunovant?
- What is Immunovant TTM EBITDA year-on-year change?
What is Immunovant annual EBITDA?
The current annual EBITDA of IMVT is -$269.98 M
What is the all time high annual EBITDA for Immunovant?
Immunovant all-time high annual EBITDA is -$65.64 M
What is Immunovant annual EBITDA year-on-year change?
Over the past year, IMVT annual EBITDA has changed by -$61.90 M (-29.75%)
What is Immunovant quarterly EBITDA?
The current quarterly EBITDA of IMVT is -$114.20 M
What is the all time high quarterly EBITDA for Immunovant?
Immunovant all-time high quarterly EBITDA is -$400.00
What is Immunovant quarterly EBITDA year-on-year change?
Over the past year, IMVT quarterly EBITDA has changed by -$52.71 M (-85.71%)
What is Immunovant TTM EBITDA?
The current TTM EBITDA of IMVT is -$404.87 M
What is the all time high TTM EBITDA for Immunovant?
Immunovant all-time high TTM EBITDA is -$400.00
What is Immunovant TTM EBITDA year-on-year change?
Over the past year, IMVT TTM EBITDA has changed by -$151.50 M (-59.80%)